A detailed history of Nuveen Asset Management, LLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 149,119 shares of RYTM stock, worth $7.73 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
149,119
Previous 142,735 4.47%
Holding current value
$7.73 Million
Previous $6.18 Million 1.0%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$35.41 - $44.37 $226,057 - $283,258
6,384 Added 4.47%
149,119 $6.12 Million
Q1 2024

May 13, 2024

SELL
$39.12 - $52.44 $36,538 - $48,978
-934 Reduced 0.65%
142,735 $6.18 Million
Q4 2023

Feb 14, 2024

BUY
$21.39 - $49.64 $44,576 - $103,449
2,084 Added 1.47%
143,669 $6.6 Million
Q3 2023

Nov 14, 2023

SELL
$15.81 - $27.8 $898,924 - $1.58 Million
-56,858 Reduced 28.65%
141,585 $3.25 Million
Q2 2023

Aug 14, 2023

BUY
$16.32 - $21.15 $2.43 Million - $3.15 Million
149,039 Added 301.67%
198,443 $3.27 Million
Q1 2023

May 15, 2023

BUY
$16.88 - $34.24 $32,291 - $65,501
1,913 Added 4.03%
49,404 $881,000
Q4 2022

Feb 14, 2023

BUY
$22.21 - $30.25 $159,934 - $217,830
7,201 Added 17.87%
47,491 $1.38 Million
Q3 2022

Nov 14, 2022

SELL
$4.3 - $30.85 $3,934 - $28,227
-915 Reduced 2.22%
40,290 $987,000
Q2 2022

Aug 15, 2022

SELL
$3.12 - $12.25 $495,284 - $1.94 Million
-158,745 Reduced 79.39%
41,205 $171,000
Q1 2022

May 16, 2022

SELL
$6.13 - $12.24 $14,883 - $29,718
-2,428 Reduced 1.2%
199,950 $2.25 Million
Q4 2021

Feb 14, 2022

SELL
$8.62 - $13.9 $100,026 - $161,295
-11,604 Reduced 5.42%
202,378 $2.02 Million
Q3 2021

Nov 12, 2021

SELL
$11.68 - $20.72 $423,680 - $751,597
-36,274 Reduced 14.49%
213,982 $2.79 Million
Q2 2021

Aug 16, 2021

BUY
$18.52 - $22.55 $1.8 Million - $2.19 Million
96,987 Added 63.28%
250,256 $4.9 Million
Q1 2021

May 17, 2021

BUY
$20.25 - $39.49 $367,800 - $717,256
18,163 Added 13.44%
153,269 $3.26 Million
Q4 2020

May 17, 2021

SELL
$21.17 - $32.61 $323,265 - $497,954
-15,270 Reduced 10.15%
135,106 $4.02 Million
Q4 2020

Feb 16, 2021

BUY
$21.17 - $32.61 $650,278 - $1 Million
30,717 Added 25.67%
150,376 $4.47 Million
Q3 2020

Nov 16, 2020

BUY
$18.13 - $30.61 $34,120 - $57,608
1,882 Added 1.6%
119,659 $2.59 Million
Q2 2020

Aug 14, 2020

BUY
$14.41 - $25.35 $161,118 - $283,438
11,181 Added 10.49%
117,777 $2.63 Million
Q1 2020

May 14, 2020

BUY
$13.16 - $22.9 $90,211 - $156,979
6,855 Added 6.87%
106,596 $1.62 Million
Q4 2019

Feb 14, 2020

BUY
$19.53 - $25.5 $508,268 - $663,637
26,025 Added 35.3%
99,741 $2.29 Million
Q3 2019

Nov 14, 2019

SELL
$18.62 - $24.51 $64,592 - $85,025
-3,469 Reduced 4.49%
73,716 $1.59 Million
Q2 2019

Aug 15, 2019

BUY
$21.11 - $28.48 $1.63 Million - $2.2 Million
77,185 New
77,185 $1.7 Million

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $2.89B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.